Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ebru Bilir has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mesalazine-associated lung fibrosis: case report and literature review

    by Nazlı Zeynep Uslu, Mustafa Hasan Adleh, Ebru Bilir, Fahad Al-Deen Kata, Merih Kalamanoğlu Balcı

  • A study on the utility of screening tests in squamous cell carcinoma (SCC) and high-grade intraepithelial lesions (HSIL) of the cervix: Evaluation of 447 cases with histopathological diagnosis

    by Süheyla Ekemen, Davut Şahin, Sadık Toprak, Ebru Bilir, Meryem Akbaş, Ümit İnCe, Serkan Erkanlı

    Introduction: Cervical cancer is one of the most common cancers in women. Precancerous lesions of the cervix can be detected with the combined use of smear testing and HPV (Human Papillomavirus) testing. International guidelines have been developed to indicate at what intervals and in which situations the tests should be performed. In this study, we examined the clinical utility of screening tests in patients with histopathologically diagnosed SCC (squamous cell carcinoma) and HSIL. Metods: Between January 2022 and June 2023, 447 patients aged 19-73 years (mean 37) with cervical biopsy results of SCC and HSIL were evaluated for the use of diagnostic tests (PAP smear and HPV test). Results: PAP smears were performed in 98.2% and HPV tests in 39.1% of all cases before histopathologic diagnosis. The most frequently detected high-risk HPV (hrHPV) was type 16. HPV testing significantly decreased with age. HPV testing was not performed in 74.2% of patients aged 51- 60 years and 80.9% of patients over 60 years. Conclusion: These cases the clinical utility and pathologic evaluation of the PAP smear were optimal. However, HPV testing practice was decreasing, especially with age. Cytologic evaluation may be misleading due to age-related hormonal withdrawal, difficulty in obtaining adequate smears, and atrophic changes. Our recommendation is to use HPV testing in all age groups, but especially in the population over 50 years of age, where cytologic difficulties may occur, HPV testing should be performed optimally until 65 years of age.

  • Open Access

    Endometrial Staining of CD56 (Uterine Natural Killer), BCL-6, and CD138 (Plasma Cells) Improve Diagnosis and Clinical Pregnancy Outcomes in Unexplained Infertility and Recurrent IVF Failures: Standardization of Diagnosis with Digital Pathology

    by Suheyla Ekemen, Cem Comunoglu, Cavit Kerem Kayhan, Ebru Bilir, Ilkay Cavusoglu, Nilay Etiler, Selcuk Bilgi, Umit Ince, Cevayir Coban, Halit Firat Erden

    In women with unexplained infertility (UI) and recurrent in vitro fertilization (IVF) failures, the etiology is often unclear. Endometrial immune perturbations and the use of immune markers associated with these dysregulations are of great interest in the diagnosis and treatment of UI. However, reliable biomarkers and standardized quantification methods are lacking. Here, to address endometrial immune dysregulation in UI patients with recurrent IVF failures, we performed endometrial tissue sampling and immunostaining of CD56 (uNK), CD138, and BCL-6. Of these cases, 57.9% had positive CD56 in the endometrial stroma, while 46.1% had positive BCL-6 in the glandular epithelium, and 14.5% of the cases were found to be positive for CD138. Combined staining rates were 60.5%, 68.4%, and 71.05% for (CD56 or BCL-6), (CD56 or CD138), and (CD56, BCL-6, or CD138), respectively. There was a significant correlation between CD56 and BCL-6 positivity, while CD138 positivity was an independent parameter. After the recommended targeted therapy, pregnancy rates were found to increase from 58.5% to 61.6% and 73.8% in CD56-positive, (CD56- or BCL-6-positive), and (CD56-, BCL-6-, or CD138-positive) cases, respectively. Notably, a retrospective evaluation of digital pathology and light microscopy results showed a significant correlation. This study suggests that the examination of CD56, BCL-6, and CD138 in the same endometrial sample may be an effective method in determining the etiology of UI and reaching an early diagnosis and treatment options. Moreover, digital pathology can be used in the evaluation of CD56 and BCL-6 to provide objective, rapid, and reliable results.